

# Bibliografía

1. Estrategia en diabetes del Sistema Nacional de Salud. Madrid: Ministerio de Sanidad y Consumo. Centro de publicaciones; 2007.
2. Grupo de estudio para la diabetes en atención primaria de salud (GEDAPS). Guía para el tratamiento de la DM 2 en la Atención. 4ª ed. 2004.
3. Arteagoitia JM, Larrañaga MI, Rodríguez JL, Fernández I, Piniés JA. Incidence, prevalence and coronary heart disease risk level in known Type 2 diabetes: a sentinel practice network study in the Basque Country, Spain. *Diabetología*. 2003;46(7):899-909.
4. Documento 2005 de Consenso entre varias sociedades científicas sobre pautas de manejo del paciente diabético tipo 2 en España. *Avances en diabetología*. 2005;21(Supl 1):1-49.
5. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med*. 1998;15(7):539-53.
6. World Health Organization. Definition, Diagnosis and classification of diabetes mellitus and its complications: Report of a WHO Consultation. Part1: Diagnosis and clasification of diabetes mellitus. Geneve: World Heath Organization; 1999.
7. Oliva J, Lobo F, Molina B, Monereo S. Direct health care costs of diabetic patients in Spain. *Diabetes Care*. 2004;27(11):2616-21.
8. Orozco-Beltran D, Gil-Guillen VF, Quirce F, Navarro-Perez J, Pineda M, Gomez-de-la-Camara A, et al. Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes in primary care. The gap between guidelines and reality in Spain. *Int J Clin Pract*. 2007;61(6):909-15.
9. Red GEDAPS. Atención primaria y diabetes mellitus tipo 2 en España. Un programa de mejora continua de la calidad asistencial. *Educación Diabetológica Profesional*. 2005;15(1):23-8.
10. Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. *Diabetes Care*. 2003;26(1):61-9.
11. Shai I, Jiang R, Manson JE, Stampfer MJ, Willett WC, Colditz GA, et al. Ethnicity, obesity, and risk of type 2 diabetes in women: a 20-year follow-up study 17. *Diabetes Care*. 2006;29(7):1585-90.
12. Meigs JB, Cupples LA, Wilson PW. Parental transmission of type 2 diabetes: the Framingham Offspring Study. *Diabetes*. 2000;49(12):2201-7.
13. Barnett AH, Eff C, Leslie RD, Pyke DA. Diabetes in identical twins. A study of 200 pairs 50. *Diabetologia*. 1981;20(2):87-93.

14. Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. *Nat Genet.* 2006;38(3):320-3.
15. Florez JC, Jablonski KA, Bayley N, Pollin TI, de Bakker PI, Shuldiner AR, et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. *N Engl J Med.* 2006;355(3):241-50.
16. Ryan EA, Imes S, Liu D, McManus R, Finegood DT, Polonsky KS, et al. Defects in insulin secretion and action in women with a history of gestational diabetes. *Diabetes.* 1995;44(5):506-12.
17. Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. *Diabetes Care.* 2002;25(10):1862-8.
18. Harder T, Rodekamp E, Schellong K, Dudenhausen JW, Plagemann A. Birth weight and subsequent risk of type 2 diabetes: a meta-analysis. *Am J Epidemiol.* 2007;165(8):849-57.
19. Rich-Edwards JW, Colditz GA, Stampfer MJ, Willett WC, Gillman MW, Hennekens CH, et al. Birthweight and the risk for type 2 diabetes mellitus in adult women. *Ann Intern Med.* 1999;130(4 Pt 1):278-84.
20. Owen CG, Martin RM, Whincup PH, Smith GD, Cook DG. Does breastfeeding influence risk of type 2 diabetes in later life? A quantitative analysis of published evidence. *Am J Clin Nutr.* 2006;84(5):1043-54.
21. Stuebe AM, Rich-Edwards JW, Willett WC, Manson JE, Michels KB. Duration of lactation and incidence of type 2 diabetes. *JAMA.* 2005;294(20):2601-10.
22. Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. *N Engl J Med.* 2001;345(11):790-7.
23. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. *Diabetes Care.* 1994;17(9):961-9.
24. Chen KW, Boyko EJ, Bergstrom RW, Leonetti DL, Newell-Morris L, Wahl PW, et al. Earlier appearance of impaired insulin secretion than of visceral adiposity in the pathogenesis of NIDDM. 5-Year follow-up of initially nondiabetic Japanese-American men. *Diabetes Care.* 1995;18(6):747-53.
25. Meisinger C, Doring A, Thorand B, Heier M, Lowel H. Body fat distribution and risk of type 2 diabetes in the general population: are there differences between men and women? The MONICA/KORA Augsburg cohort study. *Am J Clin Nutr.* 2006;84(3):483-9.
26. van Dam RM, Rimm EB, Willett WC, Stampfer MJ, Hu FB. Dietary patterns and risk for type 2 diabetes mellitus in U.S. men. *Ann Intern Med.* 2002;136(3):201-9.
27. Fung TT, Schulze M, Manson JE, Willett WC, Hu FB. Dietary patterns, meat intake, and the risk of type 2 diabetes in women. *Arch Intern Med.* 2004;164(20):2235-40.

28. Song Y, Manson JE, Buring JE, Liu S. A prospective study of red meat consumption and type 2 diabetes in middle-aged and elderly women: the women's health study. *Diabetes Care*. 2004;27(9):2108-15.
29. Liu S, Choi HK, Ford E, Song Y, Klevak A, Buring JE, et al. A prospective study of dairy intake and the risk of type 2 diabetes in women. *Diabetes Care*. 2006;29(7):1579-84.
30. Jiang R, Manson JE, Stampfer MJ, Liu S, Willett WC, Hu FB. Nut and peanut butter consumption and risk of type 2 diabetes in women. *JAMA*. 2002;288(20):2554-60.
31. van Dam RM, Hu FB. Coffee consumption and risk of type 2 diabetes: a systematic review. *JAMA*. 2005 ;294(1):97-104.
32. van Dam RM, Willett WC, Manson JE, Hu FB. Coffee, caffeine, and risk of type 2 diabetes: a prospective cohort study in younger and middle-aged U.S. women. *Diabetes Care*. 2006;29(2):398-403.
33. Iso H, Date C, Wakai K, Fukui M, Tamakoshi A. The relationship between green tea and total caffeine intake and risk for self-reported type 2 diabetes among Japanese adults. *Ann Intern Med*. 2006;144(8):554-62.
34. Schulze MB, Manson JE, Ludwig DS, Colditz GA, Stampfer MJ, Willett WC, et al. Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. *JAMA*. 2004 ;292(8):927-34.
35. Carlsson S, Hammar N, Grill V. Alcohol consumption and type 2 diabetes Meta-analysis of epidemiological studies indicates a U-shaped relationship. *Diabetologia*. 2005;48(6):1051-4.
36. Howard AA, Arnsten JH, Gourevitch MN. Effect of alcohol consumption on diabetes mellitus: a systematic review. *Ann Intern Med*. 2004;140(3):211-9.
37. Helmrich SP, Ragland DR, Leung RW, Paffenbarger RS, Jr. Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. *N Engl J Med*. 1991;325(3):147-52.
38. Lynch J, Helmrich SP, Lakka TA, Kaplan GA, Cohen RD, Salonen R, et al. Moderately intense physical activities and high levels of cardiorespiratory fitness reduce the risk of non-insulin-dependent diabetes mellitus in middle-aged men. *Arch Intern Med*. 1996;156(12):1307-14.
39. Hu FB, Sigal RJ, Rich-Edwards JW, Colditz GA, Solomon CG, Willett WC, et al. Walking compared with vigorous physical activity and risk of type 2 diabetes in women: a prospective study. *JAMA*. 1999 ;282(15):1433-9.
40. Patja K, Jousilahti P, Hu G, Valle T, Qiao Q, Tuomilehto J. Effects of smoking, obesity and physical activity on the risk of type 2 diabetes in middle-aged Finnish men and women. *J Intern Med*. 2005;258(4):356-62.
41. Gambineri A, Pelusi C, Manicardi E, Vicennati V, Cacciari M, Morselli-Labate AM, et al. Glucose intolerance in a large cohort of mediterranean women with polycystic ovary syndrome: phenotype and associated factors. *Diabetes*. 2004;53(9):2353-8.

42. Tenenbaum A, Motro M, Fisman EZ, Leor J, Freimark D, Boyko V, et al. Functional class in patients with heart failure is associated with the development of diabetes. *Am J Med.* 2003;114(4):271-5.
43. Consensus development conference on antipsychotic drugs and obesity and diabetes. *Diabetes Care.* 2004;27(2):596-601.
44. Ramaswamy K, Masand PS, Nasrallah HA. Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies. *Ann Clin Psychiatry.* 2006;18(3):183-94.
45. Hypertension. Management of Hypertension in adults in primary care. Clinical Guideline 18. National Institute for Clinical Excellence. 2004;Clinical Guideline 18.
46. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. *Lancet.* 2007;369(9557):201-7.
47. Luna B, Feinglos MN. Drug-induced hyperglycemia. *JAMA.* 2001;286(16):1945-8.
48. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care.* 1997;20(7):1183-97.
49. Brunner EJ, Shipley MJ, Witte DR, Fuller JH, Marmot MG. Relation between blood glucose and coronary mortality over 33 years in the Whitehall Study. *Diabetes Care.* 2006;29(1):26-31.
50. Levitan EB, Song Y, Ford ES, Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. *Arch Intern Med.* 2004;164(19):2147-55.
51. Sorkin JD, Muller DC, Fleg JL, Andres R. The relation of fasting and 2-h postchallenge plasma glucose concentrations to mortality: data from the Baltimore Longitudinal Study of Aging with a critical review of the literature. *Diabetes Care.* 2005;28(11):2626-32.
52. Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group. *BMJ.* 1998;317(7155):371-5.
53. Barrett-Connor E, Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study. *Diabetes Care.* 1998;21(8):1236-9.
54. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. *Arch Intern Med.* 2001;161(3):397-405.
55. Colagiuri S, Hussain Z, Zimmet P, Cameron A, Shaw J. Screening for type 2 diabetes and impaired glucose metabolism: the Australian experience. *Diabetes Care.* 2004;27(2):367-71.
56. Jimeno MJ, Molist BN, Franch NJ, Morato GJ, Otzet G, I, Pons BP. Diagnosticando la diabetes mellitus tipo 2: en atención primaria, con la glucemia basal y la hemoglobina glucosilada es suficiente. *Aten Primaria.* 2004;34(5):222-8.

57. Perry RC, Shankar RR, Fineberg N, McGill J, Baron AD. HbA<sub>1c</sub> measurement improves the detection of type 2 diabetes in high-risk individuals with nondiagnostic levels of fasting plasma glucose: the Early Diabetes Intervention Program (EDIP). *Diabetes Care*. 2001;24(3):465-71.
58. Ko GT, Chan JC, Tsang LW, Cockram CS. Combined use of fasting plasma glucose and HbA<sub>1c</sub> predicts the progression to diabetes in Chinese subjects. *Diabetes Care*. 2000;23(12):1770-3.
59. Droumaguet C, Balkau B, Simon D, Caces E, Tichet J, Charles MA, et al. Use of HbA<sub>1c</sub> in predicting progression to diabetes in French men and women: data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). *Diabetes Care*. 2006;29(7):1619-25.
60. Consensus Committee. Consensus Statement on the Worldwide Standardization of the Hemoglobin A1C Measurement: The American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation. *Diabetes Care*. 2007;30(9):2399-400.
61. Screening for type 2 diabetes mellitus in adults: recommendations and rationale. *Ann Intern Med*. 2003;138(3):212-4.
62. Waugh N, Scotland G, McNamee P, Gillett M, Brennan A, Goyder E, et al. Screening for type 2 diabetes: literature review and economic modelling. *Health Technol Assess*. 2007;11(17):1-144.
63. Grupo de Prevención Cardiovascular del PAPPs. Recomendaciones preventivas cardiovasculares. *Aten Primaria*. 2007;39(Supl 3):15-26.
64. Screening for type 2 diabetes. *Diabetes Care*. 2004;27 Suppl 1:S11-S14.
65. Kruijshoop M, Feskens EJM, Blaak EE, de Bruin TWA. Validation of capillary glucose measurements to detect glucose intolerance or type 2 diabetes mellitus in the general population. *Clinica Chimica Acta*. 2004;341(1-2):33-40.
66. Stahl M, Brandslund I, Jorgensen LG, Hyltoft PP, Borch-Johnsen K, de Fine ON. Can capillary whole blood glucose and venous plasma glucose measurements be used interchangeably in diagnosis of diabetes mellitus? *Scand J Clin Lab Invest*. 2002;62(2):159-66.
67. Colagiuri S, Sandbaek A, Carstensen B, Christensen J, Glumer C, Lauritzen T, et al. Comparability of venous and capillary glucose measurements in blood. *Diabet Med*. 2003;20(11):953-6.
68. Sandbaek A, Lauritzen T, Borch-Johnsen K, Mai K, Christiansen JS. The comparison of venous plasma glucose and whole blood capillary glucose in diagnoses of Type 2 diabetes: a population-based screening study. *Diabet Med*. 2005;22(9):1173-7.
69. Feig DS, Palda VA, Lipscombe L. Screening for type 2 diabetes mellitus to prevent vascular complications: updated recommendations from the Canadian Task Force on Preventive Health Care. *CMAJ*. 2005;172(2):177-80.

70. Santaguida PL, Balion C, Hunt D, Morrison K, Gerstein H, Raina P, et al. Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose. *Evid Rep Technol Assess (Summ )*. 2005;(128):1-11.
71. Borch-Johnsen K, Colagiuri S, Balkau B, Glumer C, Carstensen B, Ramachandran A, et al. Creating a pandemic of prediabetes: the proposed new diagnostic criteria for impaired fasting glycaemia. *Diabetologia*. 2004;47(8):1396-402.
72. Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. *BMJ*. 2007;334(7588):299.
73. Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Lau J. Long-term non-pharmacological weight loss interventions for adults with prediabetes. *Cochrane Database Syst Rev*. 2005;(2):CD005270.
74. Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, De Grauw WJ. Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. *Cochrane Database Syst Rev*. 2006;(4):CD005061.
75. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. *Lancet*. 2006;368(9541):1096-105.
76. Beletate V, El DR, Atallah A. Zinc supplementation for the prevention of type 2 diabetes mellitus. *Cochrane Database Syst Rev*. 2007;(1):CD005525.
77. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med*. 2002;346(6):393-403.
78. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. *JAMA*. 2003;290(4):486-94.
79. NICE. Clinical Guideline. Management of type 2 diabetes: Management of blood glucose. London: National Institute for Clinical Excellence; 2002.
80. IDF Clinical Guidelines Task Force. Guía global para la DM 2. Bruselas: Federación Internacional de Diabetes; 2006.
81. Anderson JW, Randles KM, Kendall CWC, Jenkins DJA. Carbohydrate and Fiber Recommendations for Individuals with Diabetes: A Quantitative Assessment and Meta-Analysis of the Evidence. *J Am Coll Nutr*. 2004;23(1):5-17.
82. Nield L, Moore H, Hooper L, Cruickshank J, Vyas A, Whittaker V, et al. Dietary advice for treatment of type 2 diabetes mellitus in adults. *Cochrane Database Syst Rev*. 2007;(3):CD004097.
83. Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Kim C, et al. Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis. *Arch Intern Med*. 2004;164(13):1395-404.

84. Norris SL, Zhang X, Avenell A, Gregg E, Brown TJ, Schmid CH, et al. Long-term non-pharmacologic weight loss interventions for adults with type 2 diabetes. *Cochrane Database Syst Rev.* 2005;(2):CD004095.
85. Williamson DF, Thompson TJ, Thun M, Flanders D, Pamuk E, Byers T. Intentional weight loss and mortality among overweight individuals with diabetes. *Diabetes Care.* 2000;23(10):1499-504.
86. American Diabetes Association. Nutrition Recommendations and Interventions for Diabetes: A position statement of the American Diabetes Association. *Diabetes Care.* 2007;30(suppl\_1):S48-S65.
87. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. *The Lancet.* 2006;368(9548):1660-72.
88. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrenbach K, et al. Bariatric surgery: a systematic review and meta-analysis. *JAMA.* 2004;292(14):1724-37.
89. Soinio M, Laakso M, Lehto S, Hakala P, Ronnema T. Dietary Fat Predicts Coronary Heart Disease Events in Subjects With Type 2 Diabetes. *Diabetes Care.* 2003;26(3):619-24.
90. Krauss RM FAU, Eckel RH FAU, Howard BF, ppel LJ FAU, niels SR FAU, ckelbaum RJ FAU, et al. AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association.
91. Garg A. High-monounsaturated-fat diets for patients with diabetes mellitus: a meta-analysis. *Am J Clin Nutr.* 1998;67(3):577S-582.
92. Farmer A, Montori V, Dinneen S, Clar C. Fish oil in people with type 2 diabetes mellitus. *Cochrane Database Syst Rev.* 2001;(3):CD003205.
93. Koppes LL, Dekker JM, Hendriks HF, Bouter LM, Heine RJ. Meta-analysis of the relationship between alcohol consumption and coronary heart disease and mortality in type 2 diabetic patients. *Diabetologia.* 2006;49(4):648-52.
94. The implementation of nutritional advice for people with diabetes. *Diabetic Medicine.* 2003;20(10):786-807.
95. Gillespie S, Kulkarni KD, Daly A. Using Carbohydrate Counting in Diabetes Clinical Practice. *Journal of the American Dietetic Association.* 1998;98(8):897-905.
96. Pi-Sunyer FX, Maggio CA, McCarron DA, Reusser ME, Stern JS, Haynes RB, et al. Multicenter randomized trial of a comprehensive prepared meal program in type 2 diabetes. *Diabetes Care.* 1999;22(2):191-7.
97. Thomas DE, Elliott EJ, Naughton GA. Exercise for type 2 diabetes mellitus. *Cochrane Database Syst Rev.* 2006;3:CD002968.
98. Sigal RJ, Kenny GP, Boule NG, Wells GA, Prud'homme D, Fortier M, et al. Effects of Aerobic Training, Resistance Training, or Both on Glycemic Control in Type 2 Diabetes: A Randomized Trial. *Ann Intern Med.* 2007;147(6):357-69.

99. Church TS, Cheng YJ, Earnest CP, Barlow CE, Gibbons LW, Priest EL, et al. Exercise capacity and body composition as predictors of mortality among men with diabetes. *Diabetes Care*. 2004;27(1):83-8.
100. Hu FB, Stampfer MJ, Solomon C, Liu S, Colditz GA, Speizer FE, et al. Physical activity and risk for cardiovascular events in diabetic women. *Ann Intern Med*. 2001;134(2):96-105.
101. Wei M, Gibbons LW, Kampert JB, Nichaman MZ, Blair SN. Low cardiorespiratory fitness and physical inactivity as predictors of mortality in men with type 2 diabetes. *Ann Intern Med*. 2000;132(8):605-11.
102. Sundstrom J, Riserus U, Byberg L, Zethelius B, Lithell H, Lind L. Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. *BMJ*. 2006;332(7546):878-82.
103. Tanasescu M, Leitzmann MF, Rimm EB, Hu FB. Physical activity in relation to cardiovascular disease and total mortality among men with type 2 diabetes. *Circulation*. 2003;107(19):2435-9.
104. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ*. 2000;321(7258):405-12.
105. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. *Ann Intern Med*. 2004;141(6):421-31.
106. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet*. 1998;352(9131):837-53.
107. Qaseem A, Vijan S, Snow V, Cross JT, Weiss KB, Owens DK, et al. Glycemic Control and Type 2 Diabetes Mellitus: The Optimal Hemoglobin A1c Targets. A Guidance Statement from the American College of Physicians. *Ann Intern Med*. 2007;147(6):417-22.
108. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. *N Engl J Med*. 2003;348(5):383-93.
109. Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. *ACCORD Blood Sugar Treatment Strategy Announcement*, February 6, 2008. <http://www.nhlbi.nih.gov/health/prof/heart/other/accord/> [Acceso febrero 2008].
110. Winocour PH. Effective diabetes care: a need for realistic targets. *BMJ*. 2002;324(7353):1577-80.
111. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, et al. Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus. *Ann Intern Med*. 2007;147(6):386-99.

112. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. *JAMA*. 2002;287(3):360-72.
113. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. *Lancet*. 1998;352(9131):854-65.
114. Donnelly LA, Doney AS, Hattersley AT, Morris AD, Pearson ER. The effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetes. *Diabet Med*. 2006;23(2):128-33.
115. Ong CR, Molyneaux LM, Constantino MI, Twigg SM, Yue DK. Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes. *Diabetes Care*. 2006;29(11):2361-4.
116. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. *Am J Med*. 1997;103(6):491-7.
117. Saenz CA, Fernandez E, I, Mataix SA, Ausejo SM, Roque M, Moher D. Metformina para la diabetes mellitus tipo 2. Revisión sistemática y metaanálisis. *Aten Primaria*. 2005;36(4):183-91.
118. Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. *Cochrane Database Syst Rev*. 2006;(1):CD002967.
119. Amori RE, Lau J, Pittas AG. Efficacy and Safety of Incretin Therapy in Type 2 Diabetes: Systematic Review and Meta-analysis. *JAMA*. 2007;298(2):194-206.
120. Goday Arno A, Franch Nadal J, Mata Cases M. Criterios de control y pautas de tratamiento combinado en la DM 2. Actualización 2004. *Medicina Clínica*. 2004;123(5):187-97.
121. Black C, Donnelly P, McIntyre L, Royle PL, Shepherd JP, Thomas S. Meglitinide analogues for type 2 diabetes mellitus. *Cochrane Database Syst Rev*. 2007;(2):CD004654.
122. Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, Rutten GE, van WC. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. *Diabetes Care*. 2005;28(1):154-63.
123. Holman RR, Cull CA, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). *Diabetes Care*. 1999;22(6):960-4.
124. Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH. Pioglitazone for type 2 diabetes mellitus. *Cochrane Database Syst Rev*. 2006;(4):CD006060.
125. Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim S. Rosiglitazone for type 2 diabetes mellitus. *Cochrane Database Syst Rev*. 2007;(3):CD006063.

126. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. *N Engl J Med.* 2007;356(24):2457-71.
127. Singh S, Loke YK, Furberg CD. Thiazolidinediones and Heart Failure: A teleo-analysis. *Diabetes Care.* 2007;30(8):2148-53.
128. Singh S, Loke YK, Furberg CD. Long-term Risk of Cardiovascular Events With Rosiglitazone: A Meta-analysis. *JAMA.* 2007;298(10):1189-95.
129. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. *JAMA.* 2007;298(10):1180-8.
130. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. *Lancet.* 2005;366(9493):1279-89.
131. Isley WL. Pioglitazone did not reduce a composite endpoint of macrovascular complications and increased risk for heart failure in type 2 diabetes with macrovascular disease. *ACP J Club.* 2006;144(2):34.
132. Riesgo cardiaco asociado a rosiglitazona. Comunicación de la AEMPS sobre datos recientemente publicados. Nota informativa 2007/08 de la AEMPS Agencia Española de Medicamentos y Productos Sanitarios. Disponible en <http://www.agemed.es/actividad/alertas/usoHumano/seguridad/rosiglitazona-mayo07.htm>; [Acceso septiembre 2007].
133. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. *N Engl J Med.* 2006;355(23):2427-43.
134. Safety Alerts for Drugs, Biologics, Devices, and Dietary Supplements. Disponible en: <http://www.fda.gov/medwatch/safety/2007/Actosmar0807.pdf> [Acceso julio 2007].
135. Rosiglitazona y pioglitazona: incremento de riesgo de fracturas en mujeres 738. Nota informativa 2007/05 de la AEMPS Agencia Española de Medicamentos y Productos Sanitarios. Disponible en <http://www.agemed.es/actividad/alertas/usoHumano/seguridad/rosiglitazona.htm> [Acceso septiembre 2007].
136. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group. *Diabetes Care.* 1998;21(1):87-92.
137. Derosa G, Gaddi AV, Piccinni MN, Salvadeo S, Ciccarelli L, Fogari E, et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial. *Diabetes Obes Metab.* 2006;8(2):197-205.
138. Garber A, Klein E, Bruce S, Sankoh S, Mohideen P. Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. *Diabetes Obes Metab.* 2006;8(2):156-63.

139. Dailey GE, III, Noor MA, Park JS, Bruce S, Fiedorek FT. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial. *Am J Med.* 2004;116(4):223-9.
140. Roberts VL, Stewart J, Issa M, Lake B, Melis R. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study. *Clin Ther.* 2005;27(10):1535-47.
141. Ko GT, Tsang PC, Wai HP, Kan EC, Chan HC. Rosiglitazone versus bedtime insulin in the treatment of patients with conventional oral antidiabetic drug failure: a 1-year randomized clinical trial. *Adv Ther.* 2006;23(5):799-808.
142. Schwartz S, Sievers R, Strange P, Lyness WH, Hollander P. Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis. *Diabetes Care.* 2003;26(8):2238-43.
143. Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. *Diabetes Care.* 2006;29(3):554-9.
144. Goudswaard AN, Furlong NJ, Rutten GE, Stolk RP, Valk GD. Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. *Cochrane Database Syst Rev.* 2004;(4):CD003418.
145. Goudswaard AN, Stolk RP, Zuithoff P, de Valk HW, Rutten GE. Starting insulin in type 2 diabetes: continue oral hypoglycemic agents? A randomized trial in primary care. *J Fam Pract.* 2004;53(5):393-9.
146. Douek IF, Allen SE, Ewings P, Gale EA, Bingley PJ. Continuing metformin when starting insulin in patients with Type 2 diabetes: a double-blind randomized placebo-controlled trial. *Diabet Med.* 2005;22(5):634-40.
147. Kvapil M, Swatko A, Hilberg C, Shestakova M. Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes. *Diabetes Obes Metab.* 2006;8(1):39-48.
148. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. *Diabetes Care.* 2005;28(2):254-9.
149. Banerjee S, Tran K, Li H, et al. Short-acting insulin analogues for diabetes mellitus: meta-analysis of clinical outcomes and assessment of cost-effectiveness [Technology Report no 87]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2007.
150. Siebenhofer A, Plank J, Berghold A, Jeitler K, Horvath K, Narath M, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. *Cochrane Database Syst Rev.* 2006;(2):CD003287.
151. Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW, Plank J, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. *Cochrane Database Syst Rev.* 2007;(2):CD005613.

152. Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. *Diabetes Care*. 2005;28(4):950-5.
153. Warren E, Weatherley-Jones E, Chilcott J, Beverley C. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. *Health Technol Assess*. 2004;8(45):iii, 1-iii,57.
154. [DRAFT] Long-acting insulin analogues for the treatment of diabetes mellitus: meta-analyses of clinical outcomes. Update of CADTH Technology Report No. 92. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2007.
155. Hu G, Jousilahti P, Qiao Q, Peltonen M, Katoh S, Tuomilehto J. The gender-specific impact of diabetes and myocardial infarction at baseline and during follow-up on mortality from all causes and coronary heart disease. *J Am Coll Cardiol*. 2005;45(9):1413-8.
156. Juutilainen A, Kortelainen S, Lehto S, Ronnema T, Pyorala K, Laakso M. Gender difference in the impact of type 2 diabetes on coronary heart disease risk. *Diabetes Care*. 2004;27(12):2898-904.
157. Natarajan S, Liao Y, Cao G, Lipsitz SR, McGee DL. Sex differences in risk for coronary heart disease mortality associated with diabetes and established coronary heart disease. *Arch Intern Med*. 2003;163(14):1735-40.
158. Whiteley L, Padmanabhan S, Hole D, Isles C. Should diabetes be considered a coronary heart disease risk equivalent?: results from 25 years of follow-up in the Renfrew and Paisley survey. *Diabetes Care*. 2005;28(7):1588-93.
159. Vaccaro O, Eberly LE, Neaton JD, Yang L, Riccardi G, Stamler J. Impact of diabetes and previous myocardial infarction on long-term survival: 25-year mortality follow-up of primary screenees of the Multiple Risk Factor Intervention Trial. *Arch Intern Med*. 2004;164(13):1438-43.
160. Wannamethee SG, Shaper AG, Lennon L. Cardiovascular disease incidence and mortality in older men with diabetes and in men with coronary heart disease. *Heart*. 2004;90(12):1398-403.
161. Becker A, Bos G, de VF, Kostense PJ, Dekker JM, Nijpels G, et al. Cardiovascular events in type 2 diabetes: comparison with nondiabetic individuals without and with prior cardiovascular disease. 10-year follow-up of the Hoorn Study. *Eur Heart J*. 2003;24(15):1406-13.
162. Cho E, Rimm EB, Stampfer MJ, Willett WC, Hu FB. The impact of diabetes mellitus and prior myocardial infarction on mortality from all causes and from coronary heart disease in men. *J Am Coll Cardiol*. 2002;40(5):954-60.
163. Eberly LE, Cohen JD, Prineas R, Yang L. Impact of incident diabetes and incident nonfatal cardiovascular disease on 18-year mortality: the multiple risk factor intervention trial experience. *Diabetes Care*. 2003;26(3):848-54.
164. Haffner SM, Lehto S, Ronnema T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med*. 1998;339(4):229-34.

165. Evans JM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. *BMJ*. 2002;324(7343):939-42.
166. Lee CD, Folsom AR, Pankow JS, Brancati FL. Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction. *Circulation*. 2004;109(7):855-60.
167. Lotufo PA, Gaziano JM, Chae CU, Ajani UA, Moreno-John G, Buring JE, et al. Diabetes and all-cause and coronary heart disease mortality among US male physicians. *Arch Intern Med*. 2001;161(2):242-7.
168. Hu FB, Stampfer MJ, Solomon CG, Liu S, Willett WC, Speizer FE, et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. *Arch Intern Med*. 2001;161(14):1717-23.
169. Hackam DG, Tan MK, Honos GN, Leiter LA, Langer A, Goodman SG. How does the prognosis of diabetes compare with that of established vascular disease? Insights from the Canadian Vascular Protection (VP) Registry. *Am Heart J*. 2004;148(6):1028-33.
170. McGin T, Guyatt G. Diagnosis. Clinical prediction Rules. In: American Medical Association, editor. *User's Guides to the Medical Literature. A manual for evidence-based clinical practice*. 2002.
171. Marrugat J, D'Agostino R, Sullivan L, Elosua R, Wilson P, Ordovas J, et al. An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas. *J Epidemiol Community Health*. 2003;57(8):634-8.
172. Marrugat J, Solanas P, D'Agostino R, Sullivan L, Ordovas J, Cordon F, et al. Estimación del riesgo coronario en España mediante la ecuación de Framingham calibrada. *Rev Esp Cardiol*. 2003;56(3):253-61.
173. Marrugat J, Subirana I, Comin E, Cabezas C, Vila J, Elosua R, et al. Validity of an adaptation of the Framingham cardiovascular risk function: the VERIFICA Study 811. *J Epidemiol Community Health*. 2007;61(1):40-7.
174. Stevens RJ, Kothari V, Adler AI, Stratton IM. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). *Clin Sci*. 2001;101(6):671-9.
175. Jimeno Mollet J, Molist Brunet N, Franch Nadal J, Serrano Borraz V, Serrano Barragán L, Gracia Giménez R. Variabilidad en la estimación del riesgo coronario en la diabetes mellitus tipo 2. *Atención Primaria*. 2005;35(1):30-6.
176. Hernández R, Choque L, Giménez M, Costa A, Márquez JI, Conget I. Estimación del riesgo coronario en pacientes con diabetes mellitus tipo 2. ¿Escala de población general o escalas específicas? *Revista Española de Cardiología*. 2004;57(6):577-80.
177. Faglia E, Manuela M, Antonella Q, Michela G, Vincenzo C, Maurizio C, et al. Risk reduction of cardiac events by screening of unknown asymptomatic coronary artery disease in subjects with type 2 diabetes mellitus at high cardiovascular risk: an open-label randomized pilot study. *Am Heart J*. 2005;149(2):e1-e6.

178. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. *Ann Intern Med.* 2002;136(2):161-72.
179. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. *Lancet.* 1998;351(9118):1755-62.
180. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. *Diabetes Care.* 2003;26(12):3264-72.
181. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. *Heart.* 2001;85(3):265-71.
182. Risk estimation and the prevention of cardiovascular disease. A national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network; 2007.
183. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. *JAMA.* 1992;268(10):1292-300.
184. Hennekens CH. Update on aspirin in the treatment and prevention of cardiovascular disease. *Am J Manag Care.* 2002;8(22 Suppl):S691-S700.
185. de GG. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. *Lancet.* 2001;357(9250):89-95.
186. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. *N Engl J Med.* 2005;352(13):1293-304.
187. Vijan S, Hayward RA. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. *Ann Intern Med.* 2004;140(8):650-8.
188. Costa J, Borges M, David C, Vaz CA. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. *BMJ.* 2006;332(7550):1115-24.
189. Allemann S, Diem P, Egger M, Christ ER, Stettler C. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials. *Curr Med Res Opin.* 2006;22(3):617-23.
190. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. *Lancet.* 2004;364(9435):685-96.

191. Knopp RH, d'Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). *Diabetes Care*. 2006;29(7):1478-85.
192. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. *The Lancet*. 2005;366(9500):1849-61.
193. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. *Lancet*. 2005;366(9493):1267-78.
194. Law M, Rudnicka AR. Statin safety: a systematic review. *Am J Cardiol*. 2006;97(8A):52C-60C.
195. Pfeffer MA, Keech A, Sacks FM, Cobbe SM, Tonkin A, Byington RP, et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. *Circulation*. 2002;105(20):2341-6.
196. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. *BMJ*. 1998;317(7160):703-13.
197. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. *Kidney Int*. 2002;61(3):1086-97.
198. Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. *Arch Intern Med*. 2005;165(12):1410-9.
199. Vijan S. Hypertension in diabetes. In: BMJ Publishing Group, editor. *Clinical Evidence*. 2006. p. 1-12.
200. Llisterri Caro JL, Rodriguez Roca GC,onso Moreno FJ, Lou AS, vison Garrote JA, Santos Rodriguez JA, et al. Control de la presión arterial en la población hipertensa española atendida en atención primaria. Estudio PRESCAP 2002. *Med Clin (Barc)*. 2004;122(5):165-71.
201. Whelton PK, Barzilay J, Cushman WC, Davis BR, Iiamathi E, Kostis JB, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Arch Intern Med*. 2005;165(12):1401-9.
202. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. *Diabetes Care*. 1998;21(4):597-603.

203. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. *New England Journal of Medicine*. 1998;338(10):645-52.
204. Mancia G, Brown M, Castaigne A, de LP, Palmer CR, Rosenthal T, et al. Outcomes with nifedipine GITS or Co-amlozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). *Hypertension*. 2003;41(3):431-6.
205. Grossman E, Messerli FH. Are calcium antagonists beneficial in diabetic patients with hypertension? *Am J Med*. 2004;116(1):44-9.
206. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet*. 2002;359(9311):1004-10.
207. Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, et al. Beta-blockers for hypertension. *Cochrane Database Syst Rev*. 2007;(1):CD002003.
208. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. *N engl J Med*. 2008;358(15):1547-59.
209. Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. *Lancet*. 2007;370:829-40.
210. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. *Lancet*. 2000;355(9200):253-9.
211. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). *Kidney International*. 2003;63(1):225-32.
212. Strippoli GF, Craig M, Craig JC. Antihypertensive agents for preventing diabetic kidney disease. *Cochrane Database Syst Rev*. 2005;(4):CD004136.
213. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. *The Lancet*. 366(9502):2026-33.
214. Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT, Jr., Whelton PK, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Archives of Internal Medicine*. 2005;165(8):936-46.
215. NICE. Clinical Guideline. Management of type 2 diabetes:Retinopathy,screening and early management. London: National Institute for Clinical Excellence; 2002.

216. Harper CA, Livingston PM, Wood C, Jin C, Lee SJ, Keeffe JE, et al. Screening for diabetic retinopathy using a non-mydratric retinal camera in rural Victoria. *Aust N Z J Ophthalmol.* 1998;26(2):117-21.
217. Lin DY, Blumenkranz MS, Brothers RJ, Grosvenor DM. The sensitivity and specificity of single-field nonmydratric monochromatic digital fundus photography with remote image interpretation for diabetic retinopathy screening: a comparison with ophthalmoscopy and standardized mydratric color photography. *Am J Ophthalmol.* 2002;134(2):204-13.
218. Hernández-Ortega MC, Soto-Pedre E, Vázquez JA, Gutiérrez MA, Asúa J. Estudio de la eficiencia de una cámara de retina no-midriática en el diagnóstico de retinopatía diabética. *Rev Clin Esp.* 1998;198(4):194-9.
219. Younis N, Broadbent DM, Vora JP, Harding SP. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. *Lancet.* 2003;361(9353):195-200.
220. Vazquez JA, Hernaez-Ortega MC, Miguel N, Soto E. Incidencia de retinopatía diabética a partir de un programa de despistaje en cámara no midriática empleado en pacientes diabéticos de la Comunidad Autónoma del País Vasco (CAPV). Investigación comisionada. Informe nº Osteba D-06-03. Vitoria-Gasteiz: Departamento de Sanidad. Gobierno Vasco; 2003.
221. National Institute for Clinical Excellence. Clinical Guideline F. Management of type 2 diabetes. Renal disease-prevention and early management. London: National Institute for Clinical Excellence; 2002.
222. Newman DJ, Mattock MB, Dawnay AB, Kerry S, McGuire A, Yaqoob M, et al. Systematic review on urine albumin testing for early detection of diabetic complications. *Health Technol Assess.* 2005;9(30):iii-163.
223. Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. *Cochrane Database Syst Rev.* 2006;(4):CD006257.
224. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. *New England Journal of Medicine.* 2001;345(12):870-8.
225. Brenner BM, Cooper ME, de ZD, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med.* 2001;345(12):861-9.
226. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *New England Journal of Medicine.* 2001;345(12):851-60.
227. Jennings DL, Kalus JS, Coleman CI, Manierski C, Yee J. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. *Diabet Med.* 2007;24(5):486-93.

228. Adriaensen H, Plaghki L, Mathieu C, Joffroy A, Vissers K. Critical review of oral drug treatments for diabetic neuropathic pain-clinical outcomes based on efficacy and safety data from placebo-controlled and direct comparative studies. *Diabetes Metab Res Rev.* 2005;21(3):231-40.
229. Wong Mc, Chung JWY, Wong TKS. Effects of treatments for symptoms of painful diabetic neuropathy: systematic review. *BMJ.* 2007;335(7610):87.
230. Wiffen PJ, McQuay HJ, Edwards JE, Moore RA. Gabapentin for acute and chronic pain. *Cochrane Database Syst Rev.* 2005;(3):CD005452.
231. Wiffen PJ, McQuay HJ, Moore RA. Carbamazepine for acute and chronic pain. *Cochrane Database Syst Rev.* 2005;(3):CD005451.
232. Hollingshead J, Duhmke RM, Cornblath DR. Tramadol for neuropathic pain. *Cochrane Database Syst Rev.* 2006;3:CD003726.
233. Eisenberg E, McNicol ED, Carr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trials. *JAMA.* 2005;293(24):3043-52.
234. Jose VM, Bhansali A, Hota D, Pandhi P. Randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy. *Diabet Med.* 2007;24(4):377-83.
235. Raskin J, Smith TR, Wong K, Pritchett YL, D'Souza DN, Iyengar S, et al. Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain. *J Palliat Med.* 2006;9(1):29-40.
236. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. *N Engl J Med.* 2005;352(13):1324-34.
237. Actualización en el tratamiento del dolor neuropático. *Infac Vol 15; N° 3.* Disponible en <http://www.osanet.euskadi.net>
238. Canadian Diabetes Association. Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. *Can J Diabetes;* 2003. Report No.: 27.
239. Vardi M, Nini A. Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus. *Cochrane Database Syst Rev.* 2007;(1):CD002187.
240. Apomorphine for erectile dysfunction. Disponible en <http://www.jr2.ox.ac.uk/bandolier/booth/SexHlth/Apo.html> [Acceso agosto 2007].
241. Gontero P, D'Antonio R, Pretti G, Fontana F, Panella M, Kocjancic E, et al. Clinical efficacy of Apomorphine SL in erectile dysfunction of diabetic men. *Int J Impot Res.* 2004;17(1):80-5.
242. Tharyan P, Gopalakrishnan G. Erectile dysfunction. *Clin Evid.* 2006;(15):1227-51.
243. Von Keitz AT, Stroberg P, Bukofzer S, Mallard N, Hibberd M. A European multi-centre study to evaluate the tolerability of apomorphine sublingual administered in

- a forced dose-escalation regimen in patients with erectile dysfunction. *BJU Int.* 2002;89(4):409-15.
244. Melnik T, Soares B, Nasselo A. Psychosocial interventions for erectile dysfunction. *Cochrane Database Syst Rev.* 2007;(3):CD004825.
  245. NZGG. Management of type 2 diabetes. New Zealand Guidelines Group; 2003.
  246. NICE. Clinical Guideline. Management of type 2 diabetes: Prevention and management of foot problems. London: National Institute for Clinical Excellence; 2003.
  247. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. *JAMA.* 2005;293(2):217-28.
  248. Mayfield JAM, Sugarman JRM. The Use of the Semmes-Weinstein Monofilament and Other Threshold Tests for Preventing Foot Ulceration and Amputation in Persons with Diabetes. *Journal of Family Practice.* 2000;49(11):S17-S29.
  249. Khan NA, Rahim SA, Anand SS, Simel DL, Panju A. Does the clinical examination predict lower extremity peripheral arterial disease? *JAMA.* 2006;295(5):536-46.
  250. McCabe CJ, Stevenson RC, Dolan AM. Evaluation of a diabetic foot screening and protection programme. *Diabet Med.* 1998;15(1):80-4.
  251. Donohoe ME, Fletton JA, Hook A, Powell R, Robinson I, Stead JW, et al. Improving foot care for people with diabetes mellitus--a randomized controlled trial of an integrated care approach. *Diabet Med.* 2000;17(8):581-7.
  252. Lavery LA, Wunderlich RP, Tredwell JL. Disease management for the diabetic foot: effectiveness of a diabetic foot prevention program to reduce amputations and hospitalizations. *Diabetes Res Clin Pract.* 2005;70(1):31-7.
  253. Anichini R, Zecchini F, Cerretini I, Meucci G, Fusilli D, Alviggi L, et al. Improvement of diabetic foot care after the Implementation of the International Consensus on the Diabetic Foot (ICDF): results of a 5-year prospective study. *Diabetes Res Clin Pract.* 2007;75(2):153-8.
  254. Valk GD, Kriegsman DM, Assendelft WJ. Patient education for preventing diabetic foot ulceration. *Cochrane Database Syst Rev.* 2005;(1):CD001488.
  255. Reiber GE, Smith DG, Wallace C, Sullivan K, Hayes S, Vath C, et al. Effect of therapeutic footwear on foot reulceration in patients with diabetes: a randomized controlled trial. *JAMA.* 2002;287(19):2552-8.
  256. Busch K, Chantelau E. Effectiveness of a new brand of stock 'diabetic' shoes to protect against diabetic foot ulcer relapse. A prospective cohort study. *Diabet Med.* 2003;20(8):665-9.
  257. Shilipak M. Diabetic nephropaty. *Clin Evidence.* 2006;15:1-15.
  258. Spencer S. Pressure relieving interventions for preventing and treating diabetic foot ulcers. *Cochrane Database Syst Rev* 2000;(3):CD002302.

259. Nelson EA, O'Meara S, Craig D, Iglesias C, Golder S, Dalton J, et al. A series of systematic reviews to inform a decision analysis for sampling and treating infected diabetic foot ulcers. *Health Technol Assess.* 2006;10(12):iii-x, 1.
260. PRODIGY Guidance. Diabetes Type 1 and 2 - foot disease . [http://www.cks.library.nhs.uk/diabetes\\_foot\\_disease](http://www.cks.library.nhs.uk/diabetes_foot_disease) [Acceso Junio 2007]
261. Smith J. Debridement of diabetic foot ulcers. *Cochrane Database Syst Rev.* 2002;(4): CD003556.
262. Bergin SM, Wraight P. Silver based wound dressings and topical agents for treating diabetic foot ulcers. *Cochrane Database Syst Rev.* 2006;(1):CD005082.
263. Bouza C, Munoz A, Amate JM. Efficacy of modern dressings in the treatment of leg ulcers: a systematic review. *Wound Repair Regen.* 2005;13(3):218-29.
264. The NHS Health Technology Assessment Programme. Randomised controlled trial of the use of three dressing regimens in the management of chronic ulcers of the foot in diabetes (proyect in progress). <http://www.hta.ac.uk/project/1357.asp> [Acceso junio 2007].
265. Shilipak M. Diabetic nephropathy. In: BMJ Publishing Group, editor. *Clinical Evidence.* London: 2006. p. 1-15.
266. Armstrong DG, Nguyen HC, Lavery LA, van Schie CH, Boulton AJ, Harkless LB. Off-loading the diabetic foot wound: a randomized clinical trial. *Diabetes Care.* 2001;24(6):1019-22.
267. Caravaggi C, Faglia E, De GR, Mantero M, Quarantiello A, Sommariva E, et al. Effectiveness and safety of a nonremovable fiberglass off-bearing cast versus a therapeutic shoe in the treatment of neuropathic foot ulcers: a randomized study. *Diabetes Care.* 2000;23(12):1746-51.
268. Katz IA, Harlan A, Miranda-Palma B, Prieto-Sanchez L, Armstrong DG, Bowker JH, et al. A randomized trial of two irremovable off-loading devices in the management of plantar neuropathic diabetic foot ulcers. *Diabetes Care.* 2005;28(3):555-9.
269. Zimny S, Meyer MF, Schatz H, Pfohl M. Applied felted foam for plantar pressure relief is an efficient therapy in neuropathic diabetic foot ulcers. *Exp Clin Endocrinol Diabetes.* 2002;110(7):325-8.
270. Cruciani M, Lipsky BA, Mengoli C, de LF. Are granulocyte colony-stimulating factors beneficial in treating diabetic foot infections?: A meta-analysis. *Diabetes Care.* 2005;28(2):454-60.
271. NICE. Guidance on the use of patient-education models for diabetes. Technology appraisal 60. London: National Institute for Clinical Excellence; 2003.
272. Loveman E, Cave C, Green C, Royle P, Dunn N, Waugh N. The clinical and cost-effectiveness of patient education models for diabetes: a systematic review and economic evaluation. *Health Technol Assess.* 2003;7(22):iii, 1-iii190.

273. Gary TL, Genkinger JM, Guallar E, Peyrot M, Brancati FL. Meta-analysis of randomized educational and behavioral interventions in type 2 diabetes. *Diabetes Educ.* 2003;29(3):488-501.
274. Ellis SE, Speroff T, Dittus RS, Brown A, Pichert JW, Elasy TA. Diabetes patient education: a meta-analysis and meta-regression. *Patient Educ Couns.* 2004;52(1):97-105.
275. van Dam HA, van der HF, van den BB, Ryckman R, Crebolder H. Provider-patient interaction in diabetes care: effects on patient self-care and outcomes. A systematic review. *Patient Educ Couns.* 2003;51(1):17-28.
276. Montori VM. Review: interventions focusing on patient behaviors in provider-patient interactions improve diabetes outcomes. *ACP J Club.* 2004;140(2):51.
277. Norris SL, Engelgau MM, Narayan KM. Effectiveness of self-management training in type 2 diabetes: a systematic review of randomized controlled trials. *Diabetes Care.* 2001;24(3):561-87.
278. Chodosh J, Morton SC, Mojica W, Maglione M, Suttorp MJ, Hilton L, et al. Meta-analysis: chronic disease self-management programs for older adults. *Ann Intern Med.* 2005;143(6):427-38.
279. Norris SL, Nichols PJ, Caspersen CJ, Glasgow RE, Engelgau MM, Jack L, et al. Increasing diabetes self-management education in community settings. A systematic review. *Am J Prev Med.* 2002;22(4 Suppl):39-66.
280. Deakin T, McShane CE, Cade JE, Williams RD. Group based training for self-management strategies in people with type 2 diabetes mellitus. *Cochrane Database Syst Rev.* 2005;(2):CD003417.
281. Dalmau Llorca MR, Garcia BG, Aguilar MC, Palau GA. Educación grupal frente a individual en pacientes diabéticos tipo 2. *Aten Primaria.* 2003;32(1):36-41.
282. Karter AJ, Ackerson LM, Darbinian JA, D'Agostino RB, Jr., Ferrara A, Liu J, et al. Self-monitoring of blood glucose levels and glycemic control: the Northern California Kaiser Permanente Diabetes registry. *Am J Med.* 2001;111(1):1-9.
283. Nathan DM, McKittrick C, Larkin M, Schaffran R, Singer DE. Glycemic control in diabetes mellitus: have changes in therapy made a difference? *Am J Med.* 1996;100(2):157-63.
284. Welschen LM, Bloemendal E, Nijpels G, Dekker JM, Heine RJ, Stalman WA, et al. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin. *Cochrane Database Syst Rev.* 2005;(2):CD005060.
285. Home glucose monitoring makes little difference in type 2 diabetes. *J Fam Pract.* 2005;54(11):936.
286. Sarol JN, Jr., Nicodemus NA, Jr., Tan KM, Grava MB. Self-monitoring of blood glucose as part of a multi-component therapy among non-insulin requiring type 2 diabetes patients: a meta-analysis (1966-2004). *Curr Med Res Opin.* 2005;21(2):173-84.

287. Farmer A, Wade A, Goyder E, Yudkin P, French D, Craven A, et al. Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial. *BMJ*. 2007;335(7611):132.
288. Oria-Pino A, Montero-Pérez FJ, Luna-Morales S, del Campo-Vazquez P, Sánchez-Guijo P. Efectividad y eficacia del autoanálisis de la glucemia capilar en pacientes con DM 2. *Med Clin (Barc)*. 2006;126(19):728-35.
289. O’Kane MJ, Bunting B, Copeland M, Coates VE; on behalf of the ESMON group. Efficacy of self monitoring of blood glucose in patients with newly type 2 diabetes (ESMON study): randomised controlled trial. *BMJ*. 2008 Apr 17. [Epub ahead of print].
290. Griffin S, Kinmonth AL. Diabetes care: the effectiveness of systems for routine surveillance for people with diabetes. *Cochrane Database Syst Rev*. 2000;(2):CD000541.
291. Renders CM, Valk GD, Griffin S, Wagner EH, Eijk JT, Assendelft WJ. Interventions to improve the management of diabetes mellitus in primary care, outpatient and community settings. *Cochrane Database Syst Rev*. 2001;(1):CD001481.



9 788445 727539

P.V.P.: 6 €

